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Purpose: Patients with chronic obstructive pulmonary disease (COPD) have
an increased incidence of pneumonia caused by Pseudomonas aeruginosa.
A respiratory fluoroquinolones alone or a beta-lactam plus a macrolide is
recommended in the presence of comorbidities according to Infectious Dis-
eases Society of America/American Thoracic Society guideline for commu-
nity-acquired pneumonia. However, few studies have directly compared
the two regimens. The present study aimed to compare the risk of pneu-
monia-related hospitalization in COPD patients treated with fluoroquino-
lones versus b-lactam/b-lactamase inhibitor combinations.
Methods: We conducted a retrospective cohort study and identified 19,876 ep-
isodes of COPD with pneumonia in the outpatients from the Taiwan National
Health Insurance Research Database (NHIRD) during 2002e2011. Using the pro-
pensity score analysis, patients receiving fluoroquinolones and b-lactam/b-lac-
tamase inhibitor combinations were matched for baseline covariates (n Z
1,296 episodes for each groups). The primary outcome was pneumonia-related
hospitalization more than 3 days after receiving antibiotics, while the second-
ary outcomes were treatment failure, 30-day mortality and medical costs.
Results: The rate of pneumonia-related hospitalization was 3.9% in the fluo-
roquinolone group and 3.5% in the b-lactam/b-lactamase inhibitor combina-
tion group (adjusted hazard ratio [HR], 1.11; 95% confidence interval [CI],
0.74e1.66). Compared with b-lactam/b-lactamase inhibitor combinations,
fluoroquinolones did not offer less treatment failure (28.2% vs. 31.3%; HR,
0.86; 95% CI, 0.73e1.02) and 30-day mortality (0.5% vs. 0.4%; HR, 1.40;
95% CI, 0.45e4.41). The total medical costs (15,847 vs. 13,644 Taiwan dol-
lars) and pneumonia-related costs (6,060 vs. 4,646 Taiwan dollars) were
similar between these two groups (both P > 0.05).
Conclusions: InCOPDoutpatientswithpneumonia,fluoroquinoloneswereasso-
ciated with similar outcomes compared with b-lactam/b-lactamase inhibitor
combinations. Our findings supported the current consensus recommendations.
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Purpose: Ciprofloxacin is a broad spectrum fluoroquinolone antimicrobial
agent. Dose adjustments to prevent toxicity effects recommended in pa-
tients with impaired renal function are various among countries. Prescribing
rationally will help to ensure the clinical utilization of this valuable antimi-
crobial drug continuously.
Methods: We conducted a retrospective study of the Ciprofloxacin usage
appropriately on 112 patients between March, 2014 and June, 2014, at a
Regional Teaching Hospital in Taichung. Assessment criteria of the Ciproflox-
acin using rationality included indication, bacterial culture and dosage forms
conversion. Cockcroft and Gault Equation calculating creatinine clearance
was used to assess patients’ renal function referring to 2013 SANFORD GUIDE
in accordance with dose adjustment in the study. Descriptive statistical
analysis has been performed.
Results: Themeanageofthesepatientswas54.5( 19.35). In thesepatients,43
of 112 (38.4%) were infectious gastroenteritis, 22 of 112 (19.6%) were urinary
tract infections, and 11 of 112 (9.8%) were neutropenia. There were 42 people
(37.5%) growth nothing in the culture, Pseudomonoas aeruginosa in total of 16
(14.3 %), and Escherichia coli in total of 9 people (8%). Five over 18 people
(27.8%) converted from injection administration to oral medication so the con-
version rate was not ideal in the hospital. The proportion of giving appropriate
dosefor renaldysfunctionpatientswas56.1% (23/41people).Thus, the study re-
sults in Ciprofloxacin reasonableness using was considered as 83.9% (94/112).
Conclusion: At present, based on the computerized physician order entry
(CPOE) system, dose adjustment was implemented on renal function impair-
ment patients directly when physicians prescribe ciprofloxacin on March
2014. The reasonable performance in the Ciprofloxacin utilization is 83.9%
currently. The higher rationality rate is expected in the future in order to
provide patients with effectiveness antimicrobial treatment and protect pa-
tients’ medication utilizing safety.
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Purpose: Excessive antibiotic consumption results in bacterial antibiotic
resistance and is a financial burden. The effect of a new antibiotic restric-
tion policy with an antimicrobial stewardship program (ASP) was assessed
in this study.
Methods: A cohort study of the ASP instituted in Nan Men general hospital, a
141-bed local hospital in Taiwan, was designed to compare pharmaceutical,
microbiological and financial changes during a 3-year period from 2011 to
2013. The cost of antimicrobials, defined daily dose (DDD) and susceptibility
to 13 antibiotics prescribed were calculated and evaluated before and after
the ASP implementation since January 1, 2012.
Results: The average monthly cost of antibiotics decreased 37.0% from
$30146.8 in 2011 to $18993.2 in 2012 (P < 0.001), and it also decreased
from 2012 to 2013 by 15.6% from $18993.2 to $16021.3 (P Z 0.022) (Figure
1). Antibiotic resistances of the two most common bacteremia found in lab-
oratory of this hospital, Escherichia coli (E. coli) and Klebsiella pneumoniae
(K. pneumoniae), were examined. The new antibiotic restriction policy
decreased or maintained antibiotic resistance to 10 antibiotics (76.9%)
against E. coli and all 13 antibiotics (100%) for K. pneumoniae. Total intrave-
nous antibiotic DDDs of the inpatients were 21932, 16816 and 14541 in 2011,
2012 and 2013, respectively. The yearly sum of all intravenous antibiotic
DDDs of all intravenous antibiotics decreased by 7391.8 from 2011 to 2013.
Total intravenous antibiotic DDDs per 100 bed-days of the inpatients were
67.1, 55.0 and 49.4 in 2011, 2012 and 2013, respectively. A total of 17.1
DDDs per 100 bed-days of inpatients decreased while from 2011 to 2013.
Figure 1 (A) The average antimicrobial cost in each month from 2011 to
2013. * Antimicrobial cost Z data*104 dollars (B) The percentage of antimi-
crobial cost in comparison to total cost of all drugs in each month.
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